TheraCoat To Raise $20M Before IPO

May 17, 2015 | The Israeli developer of treatments for urinary tract diseases, TheraCoat seeks to raise more than $20 million before it issues its public offering in New York. TheraCoat, which has created a gel technology that allows anti-cancer drugs to stick better to the bladder wall, plans to seek a company valuation of about $200 million in its IPO, which it hopes will take place sometime this year. TheraCoat was founded in 2004 and is headquartered in Ra’anana.